*	OR T1 T4
*	OR T2 T3
R1	AND Arg1:T2 Arg2:T1	
*	OR T7 T8 T9
*	OR T13 T15
R2	Has_temporal Arg1:T13 Arg2:T14	
R3	Has_qualifier Arg1:T17 Arg2:T18	
R4	Has_qualifier Arg1:T20 Arg2:T21	
R5	Has_temporal Arg1:T20 Arg2:T22	
R6	Has_temporal Arg1:T17 Arg2:T19	
*	OR T17 T20
R7	Has_index Arg1:T19 Arg2:T26	
R8	Has_index Arg1:T22 Arg2:T27	
R9	Has_index Arg1:T25 Arg2:T28	
R10	Has_value Arg1:T23 Arg2:T24	
R11	Has_temporal Arg1:T23 Arg2:T25	
R12	Has_value Arg1:T30 Arg2:T31	
R13	Subsumes Arg1:T29 Arg2:T30	
R14	Has_index Arg1:T32 Arg2:T33	
R15	Has_index Arg1:T36 Arg2:T37	
R16	Has_qualifier Arg1:T34 Arg2:T35	
R17	Has_temporal Arg1:T29 Arg2:T32	
R18	Has_temporal Arg1:T34 Arg2:T36	
R19	Has_index Arg1:T40 Arg2:T41	
R20	Has_value Arg1:T38 Arg2:T39	
R21	Has_temporal Arg1:T38 Arg2:T40	
R22	AND Arg1:T42 Arg2:T43	
*	OR T46 T45
R23	Has_qualifier Arg1:T44 Arg2:T46	
R24	Has_value Arg1:T48 Arg2:T49	
R25	Subsumes Arg1:T46 Arg2:T48	
R26	Has_value Arg1:T54 Arg2:T55	
R27	AND Arg1:T53 Arg2:T54	
*	OR T52 T53 T56
R28	Subsumes Arg1:T50 Arg2:T52	
R29	Has_mood Arg1:T50 Arg2:T51	
R30	Has_qualifier Arg1:T58 Arg2:T60	
R31	Subsumes Arg1:T60 Arg2:T59	
R32	Has_qualifier Arg1:T61 Arg2:T62	
R33	Has_multiplier Arg1:T77 Arg2:T78	
*	OR T66 T67 T68 T69 T70 T71 T72 T73 T74 T75 T76 T77
R34	Subsumes Arg1:T65 Arg2:T66	
*	OR T63 T64
R35	AND Arg1:T63 Arg2:T65	
R36	Has_index Arg1:T84 Arg2:T85	
*	OR T82 T83
R37	Has_multiplier Arg1:T82 Arg2:T81	
*	OR T97 T99 T100 T101 T102 T98
R38	Subsumes Arg1:T96 Arg2:T97	
*	OR T94 T95
R39	Subsumes Arg1:T93 Arg2:T94	
T1	Drug 29 39	ticagrelor
T2	Condition 0 11	intolerance
T3	Condition 18 25	allergy
T4	Drug 43 52	prasugrel
T7	Condition 69 75	stroke
T8	Condition 77 102	transient ischemic attack
T9	Condition 106 127	intracranial bleeding
T10	Condition 135 156	intracranial neoplasm
T11	Condition 158 197	intracranial arteriovenous malformation
T12	Condition 201 222	intracranial aneurysm
T13	Condition 231 239	bleeding
T14	Temporal 224 230	active
T15	Condition 241 351	clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding
T17	Procedure 369 389	fibrinolytic therapy
T18	Qualifier 353 368	fibrin-specific
T19	Temporal 390 425	less than 24 h before randomization
T20	Procedure 447 467	fibrinolytic therapy
T21	Qualifier 427 446	non-fibrin-specific
T22	Temporal 468 503	less than 48 h before randomization
T23	Measurement 511 525	platelet count
T24	Value 526 538	< 100.000/ÂµL
T25	Temporal 539 563	at the time of screening
T26	Reference_point 412 425	randomization
T27	Reference_point 490 503	randomization
T28	Reference_point 542 563	the time of screening
T29	Condition 571 577	anemia
T30	Measurement 579 589	hemoglobin
T31	Value 590 598	<10 g/dL
T32	Temporal 600 624	at the time of screening
T33	Reference_point 603 624	the time of screening
T34	Procedure 626 646	oral anticoagulation
T35	Qualifier 652 681	cannot be safely discontinued
T36	Temporal 682 711	for the duration of the study
T37	Reference_point 702 711	the study
T38	Measurement 713 716	INR
T39	Value 729 745	greater than 1.5
T40	Temporal 746 770	at the time of screening
T41	Reference_point 749 770	the time of screening
T42	Condition 772 799	chronic renal insufficiency
T43	Procedure 810 818	dialysis
T44	Condition 839 858	hepatic dysfunction
T45	Qualifier 832 838	severe
T46	Qualifier 820 828	moderate
T48	Measurement 860 870	Child Pugh
T49	Value 871 877	B or C
T50	Condition 898 916	bradycardia events
T51	Mood 880 894	increased risk
T52	Condition 918 928	Sick Sinus
T53	Condition 930 938	AV block
T54	Measurement 939 944	grade
T55	Value 945 954	II or III
T56	Condition 956 983	bradycardia-induced syncope
T58	Condition 1010 1022;1035 1041	complication of PCI
T59	Value 1024 1033	< 30 days
T60	Qualifier 1004 1009	acute
T61	Condition 1043 1070	concomitant medical illness
T62	Qualifier 1111 1156	is associated with a life expectancy < 1 year
T63	Procedure 1170 1174;1183 1190	oral therapy
T64	Procedure 1178 1190	i.v. therapy
T65	Drug 1196 1219	strong CYP3A Inhibitors
T66	Drug 1226 1238	ketoconazole
T67	Drug 1240 1252	itraconazole
T68	Drug 1254 1266	voriconazole
T69	Drug 1268 1281	telithromycin
T70	Drug 1283 1297	clarithromycin
T71	Drug 1299 1309	nefazodone
T72	Drug 1311 1320	ritonavir
T73	Drug 1322 1332	saquinavir
T74	Drug 1334 1344	nelfinavir
T75	Drug 1346 1355	indinavir
T76	Drug 1357 1367	atazanavir
T77	Drug 1369 1385	grapefruit juice
T78	Multiplier 1386 1393	> 1 L/d
T81	Multiplier 1621 1629	=1 doses
T82	Drug 1633 1643	ticagrelor
T83	Drug 1647 1656	prasugrel
T84	Temporal 1657 1691	within 5 days before randomisation
T85	Reference_point 1678 1691	randomisation
T87	Non-query-able 1693 1720	no written informed consent
T88	Post-eligibility 1722 1773	participation in another investigational drug study
T89	Non-query-able 1775 1807	previous enrolment in this study
T90	Pregnancy_considerations 1809 1941	for women of childbearing potential no negative pregnancy test and no agree to use reliable method of birth control during the study
T91	Pregnancy_considerations 1943 2004	Pregnancy, giving birth within the last 90 days, or lactation
T92	Non-query-able 2006 2055	inability to cooperate with protocol requirements
T93	Drug 1396 1444	CYP3A substrates with narrow therapeutic indices
T94	Drug 1451 1463	cyclosporine
T95	Drug 1465 1474	quinidine
T96	Drug 1480 1501	strong CYP3A inducers
T97	Drug 1508 1516	rifampin
T98	Drug 1517 1527	rifampicin
T99	Drug 1529 1538	phenytoin
T100	Drug 1540 1553	carbamazepine
T101	Drug 1555 1567	dexamethason
T102	Drug 1569 1582	phenobarbital
